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Background: The UGT1A1 gene encodes a responsible enzyme, UDP-glucuronosyltransferase1A1 (UGT1A1), for
bilirubin metabolism. Many mutations have already been identified in patients with inherited disorders with
unconjugated hyperbilirubinemia, such as Crigler-Najjar syndromes and Gilbert’s syndrome.
Case presentation: In this report, we presented a boy with intermittent unconjugated hyperbilirubinemia, whose
genetic analysis showed a new compound heterozygote determined by three mutations, c.211G > A (p.G71R),
c.508_510delTTC (p.F170-) and c.1456 T > G (p.Y486D) in the hotspot regions of the UGT1A1 gene (exons 1 and 5)
in Asian populations, presenting a genotype compatible with clinical picture of CNS-II. The family genetic analysis
confirmed the origin of these mutations.
Conclusion: UGT1A1 gene analysis should be performed in all cases with unexplained unconjugated
hyperbilirubinemia. The description of patients with peculiar genotypes especially including family analysis could
help explain the relationship between the genotype and phenotype,it is helpful for clinicians to predict the
outcome of the patients.
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Crigler-Najjar syndromes (CNS) are autosomal recessive
inherited inborn disorders characterized by non-hemolytic
unconjugated hyperbilirubinemia. According to serum
total bilirubin concentration (STBC), CNS are classified
into two types: type I (CNS-I), in which the STBC is
more than 25 times that of the normal level ranging
from 342 to 684 μmol/L, and type II (CNS-II), in
which it is 6-25 times with a range of STBC within
103-342 μmol/L [1,2].
Genetic variants of UDP-glucuronosyltransferase 1A1
gene (UGT1A1) resulting in the absence or decrease of
enzyme activity have been reported associating with
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gene, is the only isoform of UGTs that significantly con-
tributes to the conjugation of bilirubin for the excretion of
the bilirubin [3]. In severe CNS-I, the absence of UGT1A1
enzyme activity lead to non-hemolytic unconjugated
hyperbilirubinemia, marked jaundice and may cause bili-
rubin encephalopathy (kernicterus). However, the milder
CNS-II patients with an enzyme activity of 10% present
milder hyperbilirubinemia, and such patients can survive
into adulthood [4].
In this paper we present the case of a Chinese boy with
unconjugated hyperbilirubinemia who was diagnosed with
CNS-II and a genetic analysis of his family was performed.
As a result, three mutations were identified.Case presentation
A mainland Chinese 8-month-old boy had a history of
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with birth weight of 3700 g. At fifth day of life, jaundice
occurred with no known cause and biochemical tests
revealed severe unconjugated hyperbilirubinemia with
the levels of STBC were 400 μmol/L. For this reason,
the child was treated with phototherapy for seven days
and jaundice disappeared. However, intermittent onset
of jaundice appeared in seven months with the levels
of STBC ranging from 45.7 μmol/L to 107.3 μmol/L.
Serological tests for hepatocellular integrity, such as
ALT (alanine aminotransferase), AST (aspartate ami-
notransferase), ALP (alkaline phosphatase) activities,
serum albumin and total protein concentrations resulted
within normal range. An abdominal ultrasound exam-
ination was performed without any positive findings.
Furthermore, neonatal viral infections, red blood cell
(RBC) enzyme abnormality, hematoma, rash, or diseases
of his central nervous system were excluded. His mother
was in good health while his father presented slight jaun-
dice. His sister, a 3-year-old girl, had a history of neonatal
jaundice. After comprehensive consideration of clinical
and laboratory findings as well as his family history, we
made a diagnosis of CNS-II and deeper laboratory investi-
gations of the UGT1A1 gene was suggested.
Analysis of UGT1A1 mutation
Genomic DNA was isolated from the leucocytes of patients
after obtaining informed consent from proband and his
families. Primers for polymerase chain reaction (PCR) and
direct sequencing of UGT1A1 gene are shown in Table 1.
The sequences of the amplified DNA fragments were de-
termined directly by the use of sequencing primers.
By sequence analysis of entire UGT1A1 gene, the
proband was found to be a genetic compound heterozy-
gote for three mutations. One was a polymorphism with a
substitution of G by A at nucleotide position 211 in exon
1 (c.211G > A), resulting in the change of glycine (G) to
alanine (R) at codon 71 of the UGT1A1 enzyme (p.G71R).
The second one was a 3 bp deletion (TTC) between
nucleotides 508 and 510 in exon 1 (c.508_510delTTC),
leading to the phenylalanine (F) deletion at position
170 of the UGT1A1 enzyme (p.F170-). The last one
was a T to G transition at nucleotide position 1456 in
exon 5 (c.1456 T > G), resulting in the substitution of
tyrosine (Y) with aspartic acid (D) at codon 486 (p.Y486D).Table 1 Primers used for amplification and sequencing of the
UGT1A1 region Forward primer (5′→ 3′
Promoter & Exon 1 GAAACCTAATAAAGCTCC
Exon 2 TCATTTAAAGGGACCACGC
Exon 3 & Exon 4 ACGTAGTGCATACACCCTT
Exon 5 GAAACAGGTTTCCTTTCCCThese mutations have been associated with CNS-II ex-
cept that p.G71R occurred mostly in Gilbert syndrome
(a mild form of hereditary UGT1A1-associated syn-
dromes). His father was a carrier of heterozygous p.G71R
and p.F170-. Heterozygous p.G71R and p.Y486D were
detected in his mother. His sister carried homozygous
p.G71R and heterozygous p.Y486D. All this hereditary
information of families confirmed the inheritance and the
allelic distribution of the three mutations (Figure 1). No
mutations were detected in any of other exons and screen-
ing for the TA duplication in the UGT1A1 gene promoter
of the proband and his family members showed a wild
type genotype (6TA/6TA).
Discussion
UDP-glucuronosyltransferases (UGTs) play a critical role
in the detoxification of endogenous and exogenous lipo-
philic substrates, in particular potentially toxic substrates
such as bilirubin, by conjugating them with glucuronic
acid and thereby enhancing hydrophilicity for excretion
in bile and urine [5]. In humans, UGTs are divided into
two families, UGT1 and UGT2, based on amino acid se-
quence similarity. The UGT1 family comprises nine func-
tion enzymes (UGT1A1, UGT1A3, UGT1A4, UGT1A5,
UGT1A6, UGT1A7, UGT1A8, UGT1A9, and UGT1A10)
and four pseudogenes (UGT1A2P, UGT1A11P, UGT1A12P,
and UGT1A13P), which are encoded by a single gene at
2q37, with each UGT1A isoform consisting of a unique first
exon following commonly used exon 2 to 5 [6]. Among all
of the UGTs identified up to now, UGT1A1 is the only
relevant bilirubin-gulucuronidating enzyme which is mainly
expressed in the liver [7]. Genetic variants causing absence,
or severe reduction of UGT1A1 activity lead to mild forms
of unconjugated hyperbilirubinemia, Gilbert syndrome
(GS) and CNS-II, or a severe CNS-I form [8,9].
In this paper, we found the boy with unconjugated
hyperbilirubinemia had a compound heterozygous muta-
tion consisted of three mutations in the UGT1A1 gene
(p.G71R, p.F170- and p.Y486D). Based on the history,
along with biochemical and genetics findings, clinical
diagnosis of CNS-II was made. According to a previous
expression study, UGT1A1activities of the single homo-
zygous model of p.G71R and p.Y486D were 32.2 ± 1.6%
and 7.6 ± 0.5% of the wild-type model, respectively. The
relative enzyme activity of the double homozygous modelcoding and promoter’s regions of the UGT1A1 gene





Figure 1 Pedigree of the Chinese family with three different UGT1A1 mutations. The proband is indicated by the arrow. The square
represents the proband and his father and the circles represent the mother and the sister.
Zheng et al. BMC Pediatrics 2014, 14:267 Page 3 of 4
http://www.biomedcentral.com/1471-2431/14/267of p.G71R and p.Y486D was 6.2 ± 1.6% and that of a
heterozygous model of G71R was 60.2 ± 3.5% [10].
Polymorphism p.G71R is the most frequent genetic
cause of GS in Asian populations with a frequency of
11%-21% (Single Nucleotide Polymorphism Database
[dbSNP]). The missense mutation p.Y486D has been
reported previously in CNS-II patients in Japan and
China [11,12]. In previously reported CNS-II cases, the
p.Y486D and p.G71R often were observed in the same
heterozygous/homozygous state [13-15]. In our report,
we found something interesting. The healthy sister of
the proband who had a history of neonatal jaundice
carried homozygous p.G71R and heterozygous p.Y486D
with a suspicion of having GS. However, the mother of
the proband in whom heterozygous p.G71R and p.Y486D
were identified had always been pretty healthy. This fact
leaves us some implications. First, the p.G71R, as a poly-
morphism, is a mild disease-associated variant without the
obvious reduction of the UGT1A1 activity in vivo. Second,
the p.Y486D mutation in exon 5, one of the shared exons,
is deleterious as it could affect the glucuronidation of all
the isoforms (UGT1A1 to 1A10) expressed from UGT1
family [14]. However, p.Y486D in heterozygous condition
needs to combine with some other deleterious mutations
to cause clinically CNS-II.
The deletion mutation p.F170-, found in our patient,
has been described in CNS-I and CNS-II in Italian
population [12,16]. Deletion of a phenylalanine at codon
170 abolished a conserved double-phenylalanine site in a
highly conserved strikingly hydrophobic region between
amino acids 161 and 180 (amino-terminal region of the
UGT1A1 enzyme). Moreover, exon 1, the location of the
deletion mutation, encoded the substrate specific region
of UGT1A1 accounting for 80% of the bilirubin transferase
activity. So, this mutation determined CNS-I and CNS-II
phenotypes in homozygous and heterozygous conditions,respectively, as the highly deleterious deletion could
effectively eliminate the UGT1A1 enzyme activity [16].
In our report, the phenotypes associated with our patient
(CNS-II) and his father who all carried heterozygous
p.F170- suggested that p.Y486D only in compound
heterozygous with deleterious p.F170- could cause ob-
vious jaundice confirmed the recessive inheritance of
CNS-II and the compound heterozygote did not deter-
mine the complete abolition of UGT1A1 enzyme function,
but resulted only in a mild phenotype characterized
at variable levels of STBC, with high concentrations at
birth followed by a progressive declining over time up to
reach values slightly above the normal ranges. And, the
clinical phenotype observed was considered compatible
with CNS-II. In consideration of the previously reported
literatures and our report, we considered that exons 1 and
5 probably were hotspot regions of the UGT1A1 gene in
Asian populations especially in Japanese and Chinese
and p.G71R and p.Y486D were two most common var-
iants leading to UGT1A1 genetically-associated uncon-
jugated hyperbilirubinemia.
Conclusions
We identified a compound heterozygous mutation,
p.G71R/p.F170-/p.Y486D, in UGT1A1 gene in an 8-
month-old Chinese boy with intermittent hyperbilirubi-
nemia who was clinically diagnosed as CNS-II. UGT1A1
gene analysis should be performed in all cases with unex-
plained unconjugated hyperbilirubinemia. The description
of patients with peculiar genotypes especially including
family analysis could help explain the relationship between
the genotype and phenotype, helping clinicians predict the
outcome of the patients. In addition, as hotspot regions of
the UGT1A1 gene, exons 1 and 5 need to be commonly
analyzed in Asian populations especially in Japanese and
Chinese.
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